Gilead Sciences Inc
Gilead Sciences is an American biopharmaceutical company specializing in the research, development, and commercialization of antiviral drugs for the treatment of HIV, hepatitis B and C, as well as other infectious diseases.
Price history of Gilead Sciences Inc
Price history of Gilead Sciences Inc
Performance & Momentum
Gilead Beats Revenue, Cuts Outlook
Gilead Sciences posted a stronger-than-expected first quarter, with revenue up 4.4% to $6.96 billion and adjusted earnings per share of $2.03, also above consensus. Growth in HIV business and solid operating performance continue to support the company, while management now targets about $30.2 billion in full-year revenue, close to market expectations. However, the market focused mainly on the sharp downgrade to 2026 earnings guidance, after the inclusion of significant R&D and financing-related costs. This pressure on margins and adjusted profit could weigh on the stock in the near term, despite an oncology pipeline that remains closely watched by investors.
Strategic Analysis
Gilead Sciences Inc • 2026
Gilead Sciences holds a specialist biopharmaceutical position focused on infectious diseases, with a strong historical base in HIV and hepatitis. Its model relies on proprietary, high medical-value treatments, supported by an ability to extend the life of its franchises and to fund innovation through recurring cash flows.
- Reference position in HIV and antivirals, with established franchises that are difficult to challenge
- Exposure to high-margin specialty treatments with strong commercial stickiness
- Favorable stock market track record across multiple time horizons, reflecting lasting investor confidence
- Structural dependence on a few major therapeutic pillars, leaving it exposed to the gradual erosion of its franchises
- High sensitivity to pipeline renewal and clinical success in a highly competitive sector
Momentum is clearly solid and reflects a constructive market dynamic, with a favorable underlying trend across multiple time horizons. This improvement suggests that investors are placing greater value on revenue visibility and the group’s ability to defend its key positions, even if the sustainability of this trend will depend on product portfolio renewal and the success of the next growth drivers.
Similar stocks to Gilead Sciences Inc
Recent News
Gilead Sciences Inc
Gilead Advances on Arcellx Despite Challenge
3 weeks agoGilead Sciences remains in focus as regulatory approvals tied to its acquisition of Arcellx are finalized. The deal strengthens its strategy in innovative therapies and supports its medium-term growth outlook. This step is generally positive for the group, as it reinforces its pipeline and its presence in cutting-edge treatments. At the same time, a shareholder resolution backed by the AHF is calling for greater transparency on patent exclusivity, an issue that could fuel debate over the company’s commercial strategy. The stock impact remains broadly constructive for now, but regulatory pressure and governance concerns may temper investor enthusiasm in the short term.
Gilead Gets Lift From New Lenacapavir Investment
1 month agoGilead Sciences is benefiting from another positive development around its lenacapavir drug. The U.S. State Department, PEPFAR and The Global Fund plan to increase investment to broaden access to this injectable HIV prevention treatment, with a target of reaching up to 3 million people in high-incidence countries by 2028. The move strengthens lenacapavir’s commercial outlook and underscores institutional interest in the innovation, which could support Gilead’s medium-term growth prospects. Despite criticism over drug pricing, the news is broadly positive for GILD and could improve market sentiment toward the stock.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
